Continuous Glucose Monitoring Market: Market Size & Forecast 2026

CGM systems consist of a subcutaneous sensor, a transmitter, and a receiver or smartphone app that displays glucose readings every few minutes. Adoption has shifted from niche use among Type 1 diabetes patients toward mainstream use across Type 2 and even non-diabetic wellness segments. The market's combination of recurring sensor revenue and expanding indications underpins its double-digit annual growth.

• •Global valuation near $11.8 billion in 2025 with a CAGR of approximately 15.4%.
• •CGM devices replace finger-stick testing with continuous, real-time glucose data and trend alerts.
• •Recurring sensor sales drive most revenue, as users replace sensors every 7 to 14 days.

Rising diabetes incidence worldwide is the single largest demand driver, with more than half a billion adults now living with the condition. Wider reimbursement from Medicare, the UK's NHS, and major U.S. insurers has removed cost barriers, while sensor miniaturization and longer wear times have improved the user experience. Growing clinical evidence linking CGM use to better HbA1c outcomes is encouraging physicians to prescribe these devices earlier.

• •Global diabetes prevalence continues to climb, expanding the eligible patient pool.
• •Insurance coverage now extends to many Type 2 diabetes patients on insulin therapy.
• •Clinical guidelines increasingly endorse CGM as standard of care for insulin-managed diabetes.

By component, sensors account for the majority of revenue, followed by transmitters and receivers. By end user, hospitals and home-care settings dominate, while sports, wellness, and non-diabetic use represent emerging niches. North America leads on revenue thanks to favorable reimbursement, while Asia-Pacific is the fastest-growing region as healthcare access expands.

• •Sensors form the largest product segment, with recurring replacement purchases.
• •North America holds the largest share; Asia-Pacific shows the highest growth rate.
• •Type 1 diabetes remains the core user base, with Type 2 diabetes expanding fastest.

What are the recent trends and outlook?

Factory-calibrated sensors that eliminate finger-stick calibration and 14- to 180-day implantable sensors are redefining patient expectations. Integration with automated insulin delivery (AID) systems and AI-driven analytics is making CGM data more actionable for both patients and clinicians. Beyond diabetes, CGMs are being explored for metabolic health, athletic performance, and preventive care, signaling continued category expansion through the late 2020s.

• •Longer-wear and implantable sensors are reducing user burden and expanding addressable markets.
• •AI-powered analytics are improving glycemic prediction and personalized dosing.
• •Non-diabetic and wellness applications are emerging as a new growth frontier.